Dosage form |
Process |
Raw materials |
Characteristics of the product |
Ref. no. |
Ofloxacin-loaded pellets |
Extrusion-spheronization |
Ethyl cellulose, sodium bicarbonate, Eudragit RL 30D |
Floats and retards the release over 8 h |
[13] |
Norfloxacin Microballoons |
Emulsion solvent diffusion |
Eudragit®L100, Eudragit®RS 100 |
Intestinal pH dependent release |
[14] |
Bumetanide pellets |
Fluid bed layering and coating |
Eudragit®RS 100, Tri ethyl citrate, sodium chloride |
Porous nature with sustained release |
[15] |
Levodopa novel unfolded CR-GRDF |
Solvent evaporation |
Gelatin, L-polylactic acid, ethyl cellulose, carbidopa, Eudragit®S 100 |
Sustained drug release over 9 h |
[16] |
Novel floating effervescent |
Ion exchange resins |
Eudragit®RS 100 and sodium bi carbonate |
Floated over 24 h |
[17] |
Diclofenac potassium pellets |
Extrusion–spheronization |
Eudragit®NE 30D, Eudragit®RS 30D and Kollicoat®SR 30D |
Controls the release and fluctuations |
[18] |
Metformin hydrochloride matrix tablets |
Direct compression |
Polyethylene oxide and Eudragit®L100 |
Unaffected by gastric pH |
[19] |
Levodopa floating coated mini-tabs |
Melt granulation and compression |
Eudragit®RL 30D, acetyl tri ethyl citrate |
Buoyancy over 13 h and sustained release over 20 h |
[20] |
Riboflavin unfolding dosage form |
Accordion pill technology |
Eudragit® L and Eudragit® S plasticized with tri ethyl citrate |
prolongs the gastric residence time |
[21] |
Diltiazem hydrochloride floating microspheres |
Ionotropic gelation method |
sodium alginate, calcium chloride, calcium carbonate, Eudragit®RS 30D and chitosan |
Excellent floating ability with suitable drug release pattern over 24 h |
[22] |
Rabeprazole sodium enteric coated tablet |
Wet granulation and direct compression |
Colorcoat EC4S, Mannitol SD 200, microcrystalline cellulose and kollidon CL |
Provides resistance to acidic environment and facilitates sustained release in alkaline conditions |
[23] |
Matrix tablet |
Direct compression |
Kollidon SR, Propanolol hydrochloride |
Sustained the release over 24 h with fickian diffusion |
[24] |
Riboflavin microballoon |
Emulsion solvent diffusion |
Eudragit®RS 100 and hydroxyl propyl methyl cellulose |
Urinary excretion was sustained |
[25] |
Ketoprofen floating microparticles |
Emulsion solvent diffusion |
Eudragit®S 100 and Eudragit®RL 100 |
Gave higher percentage yield and better buoyancy |
[26] |
Riboflavin microballoons |
Emulsion solvent diffusion |
Eudragit®S 100, HPMC, PVA, dichloro methane and ethanol |
Drug release from microballoons and total urinary excretion were strongly correlated |
[27] |
Verapamil floating pellets |
Wet granulation and spheronization |
Povidone K 30, Eudragit®NE 30 D, Eudragit®L 30 D, triethyl citrate, talcum |
Floated for 6 h and gave improved pharmacokinetics than the conventional tablet |
[28] |
Microballoons |
Emulsion solvent diffusion |
Eudragit®S 100 and monostearin |
Optimum temperature of 40 °C gave better buoyancy and retarded release due to smooth surface. Drug entrapment was high due to higher distribution coefficient |
[29] |
Riboflavin microballoons |
Emulsion solvent diffusion |
Eudragit®RS 100 and HPMC |
Gamma scintigraphy technique confirms that the floating microballoons retained for longer time period in comparison to the non-floating in fed conditions, both half life and the total urinary excretion of drug increases significantly |
[30] |
Avidin microstructured Delivery |
Microfabrication technology |
Poly (methyl methacrylate) (PMMA) and Lectin |
Adheres to the intestinal mucosa, prevents drug degradation and sustains the release |
[32] |